Drug Profile
VRC-HIVDNA044-00-VP
Latest Information Update: 29 Jun 2017
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases; Vaccine Research Center
- Developer HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention) in USA (IM)